Analysis for acute grade 3-4 GVHD
| Variable . | Cohort size . | Relative risk (95% CI) . | P . |
|---|---|---|---|
| Early: AML CR1, CML with CP1 less than 1 y from diagnosis, and MDS (RA) | 534 | ||
| Recip ligand status | |||
| All KIR-L present | 181 | 1.00 (reference) | — |
| Missing 1 or more KIR-L | 353 | 0.95 (0.68-1.33) | .75 |
| HLA match status | |||
| KIR-L MM (GVH) | 44 | 1.00 (reference) | — |
| HLA MM only | 188 | 1.00 (0.57-1.75) | .99 |
| HLA matched | 302 | 0.54 (0.31-0.94) | .03 |
| Early CML chronic phase more than 1 y from diagnosis | 479 | ||
| Recip ligand status | |||
| All KIR-L present | 170 | 1.00 (reference) | — |
| Missing 1 or more KIR-L | 309 | 1.58 (1.13-2.22) | .008 |
| HLA match status | |||
| KIR-L MM (GVH) | 60 | 1.00 (reference) | — |
| HLA MM only | 209 | 0.96 (0.63-1.47) | .86 |
| HLA matched | 210 | 0.52 (0.34-0.80) | .003 |
| ATG/TCD status | |||
| ATG given and TCD | 26 | 1.00 (reference) | — |
| ATG but no TCD | 21 | 1.50 (0.54-4.16) | .43 |
| No ATG but TCD | 68 | 0.65 (0.26-1.66) | .37 |
| No ATG or TCD | 364 | 2.23 (1.04-4.78) | .04 |
| Intermediate: AML more than CR1 or first relapse, CML more than CP1 or AP, MDS no excess blasts | 702 | ||
| Recip ligand status | |||
| All KIR-L present | 246 | 1.00 (reference) | — |
| Missing 1 or more KIR-L | 456 | 1.19 (0.89-1.59) | .24 |
| HLA match status | |||
| KIR-L MM (GVH) | 71 | 1.00 (reference) | — |
| HLA MM only | 312 | 0.97 (0.64-1.48) | .89 |
| HLA matched | 319 | 0.68 (0.44-1.03) | .07 |
| Advanced: AML in relapse, CML BC, MDS (RAEB/RAEBT) | 338 | ||
| Recip ligand status | |||
| All KIR-L present | 118 | 1.00 (reference) | — |
| Missing 1 or more KIR-L | 220 | 0.75 (0.53-1.07) | .11 |
| Variable . | Cohort size . | Relative risk (95% CI) . | P . |
|---|---|---|---|
| Early: AML CR1, CML with CP1 less than 1 y from diagnosis, and MDS (RA) | 534 | ||
| Recip ligand status | |||
| All KIR-L present | 181 | 1.00 (reference) | — |
| Missing 1 or more KIR-L | 353 | 0.95 (0.68-1.33) | .75 |
| HLA match status | |||
| KIR-L MM (GVH) | 44 | 1.00 (reference) | — |
| HLA MM only | 188 | 1.00 (0.57-1.75) | .99 |
| HLA matched | 302 | 0.54 (0.31-0.94) | .03 |
| Early CML chronic phase more than 1 y from diagnosis | 479 | ||
| Recip ligand status | |||
| All KIR-L present | 170 | 1.00 (reference) | — |
| Missing 1 or more KIR-L | 309 | 1.58 (1.13-2.22) | .008 |
| HLA match status | |||
| KIR-L MM (GVH) | 60 | 1.00 (reference) | — |
| HLA MM only | 209 | 0.96 (0.63-1.47) | .86 |
| HLA matched | 210 | 0.52 (0.34-0.80) | .003 |
| ATG/TCD status | |||
| ATG given and TCD | 26 | 1.00 (reference) | — |
| ATG but no TCD | 21 | 1.50 (0.54-4.16) | .43 |
| No ATG but TCD | 68 | 0.65 (0.26-1.66) | .37 |
| No ATG or TCD | 364 | 2.23 (1.04-4.78) | .04 |
| Intermediate: AML more than CR1 or first relapse, CML more than CP1 or AP, MDS no excess blasts | 702 | ||
| Recip ligand status | |||
| All KIR-L present | 246 | 1.00 (reference) | — |
| Missing 1 or more KIR-L | 456 | 1.19 (0.89-1.59) | .24 |
| HLA match status | |||
| KIR-L MM (GVH) | 71 | 1.00 (reference) | — |
| HLA MM only | 312 | 0.97 (0.64-1.48) | .89 |
| HLA matched | 319 | 0.68 (0.44-1.03) | .07 |
| Advanced: AML in relapse, CML BC, MDS (RAEB/RAEBT) | 338 | ||
| Recip ligand status | |||
| All KIR-L present | 118 | 1.00 (reference) | — |
| Missing 1 or more KIR-L | 220 | 0.75 (0.53-1.07) | .11 |
HLA match represents antigen level match at HLA-A, B and allele match at DRB1. The regression adjustments applied were the same as in Table 1.
KIR-L MM (GVH) indicates KIR ligand mismatch in GVH direction; and MM, mismatch. Additional abbreviations are explained in Table 1.